Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Tonix Pharmaceuticals Holding (TNXP) Gross Profit: 2023-2025

Historic Gross Profit for Tonix Pharmaceuticals Holding (TNXP) over the last 2 years, with Sep 2025 value amounting to $1.9 million.

  • Tonix Pharmaceuticals Holding's Gross Profit rose 51.78% to $1.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.5 million, marking a year-over-year increase of 50.90%. This contributed to the annual value of $2.3 million for FY2024, which is 23.06% down from last year.
  • According to the latest figures from Q3 2025, Tonix Pharmaceuticals Holding's Gross Profit is $1.9 million, which was up 250.94% from -$1.3 million recorded in Q2 2025.
  • Tonix Pharmaceuticals Holding's Gross Profit's 5-year high stood at $1.9 million during Q3 2025, with a 5-year trough of -$1.3 million in Q2 2025.
  • Moreover, its 3-year median value for Gross Profit was $1.4 million (2024), whereas its average is $832,333.
  • Its Gross Profit has fluctuated over the past 5 years, first decreased by 21.55% in 2024, then soared by 80.78% in 2025.
  • Over the past 3 years, Tonix Pharmaceuticals Holding's Gross Profit (Quarterly) stood at $1.4 million in 2023, then fell by 0.92% to $1.4 million in 2024, then soared by 51.78% to $1.9 million in 2025.
  • Its Gross Profit was $1.9 million in Q3 2025, compared to -$1.3 million in Q2 2025 and $1.5 million in Q1 2025.